Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.
Line UhrenholtRobin ChristensenLene DreyerEllen Margrethe HaugeA SchlemmerAnne Gitte LoftMnb RaschHans Christian HornK H GadeRené Drage ØstgårdPeter C TaylorKirsten DuchSalome KristensenPublished in: Scandinavian journal of rheumatology (2023)
Disease activity-guided tapering of biologics in patients with inflammatory arthritis enabled one-third to achieve ≥ 50% biologic reduction, while disease activity between groups remained equivalent. Flares were more frequent in the tapering group but were managed with rescue therapy.
Keyphrases
- disease activity
- rheumatoid arthritis
- open label
- phase iii
- phase ii
- study protocol
- rheumatoid arthritis patients
- ankylosing spondylitis
- clinical trial
- systemic lupus erythematosus
- juvenile idiopathic arthritis
- oxidative stress
- double blind
- phase ii study
- placebo controlled
- randomized controlled trial
- stem cells
- radiation therapy